Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Undersøgelse af ITI-1284 som monoterapibehandling hos patienter med generaliseret angstlidelse

2. november 2026 opdateret af: Intra-Cellular Therapies, Inc.

En multicenter, randomiseret, dobbeltblind, placebokontrolleret undersøgelse til vurdering af effektiviteten, sikkerheden og tolerabiliteten af ​​ITI-1284 som en supplerende behandling hos patienter med generaliseret angstlidelse, som har en utilstrækkelig respons på behandling af generaliseret angstlidelse

This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ITI-1284 as monotherapy treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD in patients who have had inadequate response to generalized anxiety disorder treatment.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

570

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Blagoevgrad, Bulgarien, 2700
        • Rekruttering
        • Medical Center Sv Dimitar Blagoevgrad
      • Kardzhali, Bulgarien, 6600
        • Rekruttering
        • Medical Center Lifemed
      • Pleven, Bulgarien, 5800
        • Rekruttering
        • Medical Center Medconsult-Pleven
      • Plovdiv, Bulgarien, 4004
        • Rekruttering
        • Medical Center Mentalcare OOD
      • Rousse, Bulgarien, 7003
        • Rekruttering
        • Mental Health Center - Rousse
      • Sofia, Bulgarien, 1680
        • Rekruttering
        • Medical Center Intermedica, OOD
      • Sofia, Bulgarien, 1408
        • Rekruttering
        • DCC 'Sv. Vrach and Sv. Sv. Kuzma and Damyan', OOD
      • Sofia, Bulgarien, 1510
        • Rekruttering
        • Medical Center Hera EOOD
      • Targovishte, Bulgarien, 7700
        • Rekruttering
        • Medical center - VAS OOD
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35294
        • Rekruttering
        • University of Alabama at Birmingham
    • Arkansas
      • Little Rock, Arkansas, Forenede Stater, 72211
        • Rekruttering
        • Woodland International Research Group
      • Rogers, Arkansas, Forenede Stater, 72758
        • Rekruttering
        • Woodland Research Northwest
    • California
      • Culver City, California, Forenede Stater, 90230
        • Rekruttering
        • Proscience Research Group
      • Encino, California, Forenede Stater, 91316
        • Rekruttering
        • Wake Research PRI Encino
      • Encino, California, Forenede Stater, 91316
        • Rekruttering
        • Leading Edge Research
      • Los Angeles, California, Forenede Stater, 90025
        • Rekruttering
        • CalNeuro Research
      • Oceanside, California, Forenede Stater, 92056
        • Rekruttering
        • Excell Research Inc
      • Sherman Oaks, California, Forenede Stater, 91403
        • Rekruttering
        • California Neuroscience Research
      • Upland, California, Forenede Stater, 91786
        • Afsluttet
        • Pacific Clinical Research Medical Group
      • Walnut Creek, California, Forenede Stater, 94596
        • Rekruttering
        • Sunwise Clinical Research
    • Connecticut
      • Farmington, Connecticut, Forenede Stater, 06032
        • Rekruttering
        • University of Connecticut Health Center
    • Florida
      • Gainesville, Florida, Forenede Stater, 32607
        • Afsluttet
        • Sarkis Clinical Trials
      • Miami, Florida, Forenede Stater, 33176
        • Rekruttering
        • Miami Dade Medical Research Institute
      • Tampa, Florida, Forenede Stater, 33613
        • Rekruttering
        • University of South Florida
    • Georgia
      • Decatur, Georgia, Forenede Stater, 30030
        • Rekruttering
        • iResearch Atlanta LLC
    • Mississippi
      • Flowood, Mississippi, Forenede Stater, 39232
        • Rekruttering
        • Precise Clinical Research, Inc.
    • New York
      • Brooklyn, New York, Forenede Stater, 11235
        • Rekruttering
        • SPRI Clinical Trials, LLC
      • Buffalo, New York, Forenede Stater, 14215
        • Rekruttering
        • University of Buffalo
      • Staten Island, New York, Forenede Stater, 10314
        • Rekruttering
        • Richmond Behavioral Associates
    • Ohio
      • Columbus, Ohio, Forenede Stater, 43210
        • Rekruttering
        • The Ohio State University
    • Oklahoma
      • Norman, Oklahoma, Forenede Stater, 73071
        • Rekruttering
        • Sooner Clinical Research
    • Pennsylvania
      • Media, Pennsylvania, Forenede Stater, 19063
        • Rekruttering
        • Suburban Research Associates
    • Texas
      • Dallas, Texas, Forenede Stater, 75243
        • Rekruttering
        • Relaro Medical Trials
    • Washington
      • Bellevue, Washington, Forenede Stater, 98007
        • Rekruttering
        • Northwest Clinical Research Center
      • Bialystok, Polen, 15272
        • Rekruttering
        • Prywatne Gabinety Lekarskie PROMEDICUS
      • Bydgoszcz, Polen, 85-080
        • Rekruttering
        • Przychodnia Srodmiescie SP. z o.o.
      • Gdansk, Polen, 80 283
        • Rekruttering
        • Centrum Zdrowia Alcea
      • Leszno, Polen, 64-100
        • Rekruttering
        • Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS
      • Torun, Polen, 87 100
        • Rekruttering
        • Agnieszka Nowakowska Rudzka Gabinet Lekarski TCP Neuromed
      • Belgrade, Serbien, 11000
        • Rekruttering
        • University Clinical Center of Serbia
      • Belgrade, Serbien, 11000
        • Rekruttering
        • Institute of Mental Health Serbia
      • Belgrade, Serbien, 11000
        • Rekruttering
        • Clinical Center Dr Dragisa Misovic Dedinje
      • Belgrade, Serbien, 11000
        • Rekruttering
        • University Clinical Center of Serbia 1
      • Kovin, Serbien, 26220
        • Rekruttering
        • Special Neuropsychiatric Hospital Kovin
      • Kragujevac, Serbien, 34000
        • Rekruttering
        • University Clinical Center Kragujevac
      • Niš, Serbien, 18000
        • Rekruttering
        • University Clinical Center NIS
      • Novi Kneževac, Serbien, 23330
        • Rekruttering
        • Specialized Hospital for Neuropsychiatric Diseases Sveti Vracevi
      • Bratislava, Slovakiet, 821 01
        • Rekruttering
        • Psychiatricka Ambulancia Mentum S.R.O.
      • Rimavská Sobota, Slovakiet, 979 01
        • Rekruttering
        • Psychiatricka Ambulancia Psycholine S.R.O.
      • Svidník, Slovakiet, 08901
        • Rekruttering
        • Centrum Zdravia R.B.K. S.R.O. Poliklinika Medic Sk
      • Vranov nad Topľou, Slovakiet, 093 01
        • Rekruttering
        • Crystal Comfort s.r.o.

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Provide written informed consent before the initiation of any study specific procedures;

  • At Screening, meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) diagnostic criteria for moderate or severe GAD (current GAD) as confirmed by the Investigator or Sponsor-approved rater using the Structured Clinical Interview for DSM-5 Clinical Trials Version (SCID-5-CT), and meets all of the following at Screening and Baseline:

    • HAM-A Total score of ≥ 22;
    • HAM-A Items 1 (anxious mood) and 2 (tension) scores ≥ 2;
    • CGI-S score of ≥ 4;
  • History of inadequate response (< 50% improvement in anxiety symptoms as measured by the modified Antidepressant Treatment Response Questionnaire [ATRQ] for GAD) to at least 2 of the following GAD-approved treatments: paroxetine, venlafaxine XR, duloxetine, escitalopram, or buspirone taken at an adequate dose (that is, at least a minimum total daily dose of paroxetine 20 milligram [mg], venlafaxine XR 75mg, duloxetine 60 mg, escitalopram 10mg, or buspirone 20 mg) and duration (ie, for at least 6 weeks prior to Screening) for the treatment of ongoing GAD symptoms.

Exclusion Criteria:

  • Within the patient's lifetime, has one of the following confirmed DSM-5-TR psychiatric diagnoses:

    • Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder;
    • Bipolar Disorder;
  • MADRS total score > 18 at Screening or Baseline;

  • In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during his/her participation in the study or

    • At Screening, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the C-SSRS within 6 months prior to Screening or, at Baseline, the patient scores "yes" on Suicidal Ideation Items 4 or 5 since the Screening Visit;
    • At Screening, the patient has had 1 or more suicidal attempts within the 2 years prior to Screening;
    • At Screening or Baseline MADRS Item 10 score ≥ 5; or
    • The patient is considered to be an imminent danger to him/herself or others based on the assessment of the Investigator;
  • Lifetime history of failure to respond to > 3 of the approved treatments for GAD (ie, paroxetine, venlafaxine XR, duloxetine, escitalopram, or buspirone) at an adequate dose (that is, at least a minimum total daily dose of paroxetine 20 mg, venlafaxine XR 75mg, duloxetine 60 mg, escitalopram 10mg, or buspirone 20 mg) and for an adequate duration (ie, at least 6 weeks)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: ITI-1284 10mg

ITI-1284 10 mg tablet, taken once daily, sublingual administration.

ITI-1284 10 mg tablet, taken once daily, sublingual administration.

Eksperimentel: ITI-1284 20mg

ITI-1284 20 mg tablet, taken once daily, sublingual administration.

ITI-1284 20 mg tablet, taken once daily, sublingual administration.

Placebo komparator: Placebo

Matching placebo tablet, taken once daily, sublingual administration

Matching placebo tablet, taken once daily, sublingual administration

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Hamilton Anxiety Rating Scale (HAM-A)
Tidsramme: Week 6

The HAM-A Scale is a clinician-rated scale measuring both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). It is comprised of 14 items that are rated on a 5-point scale ranging from 0 = not present to 4 = very severe, disabling symptoms. The HAM-A total score ranges from 0 to 56 with a higher score indicating increased severity of anxiety symptoms.

Week 6

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Clinical Global Impression Scale-Severity (CGI-S)
Tidsramme: Week 6

The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients)

Week 6

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Intra-Cellular Therapies,Inc. Clinical Trial, Intra-Cellular Therapies, Inc.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

21. november 2024

Primær færdiggørelse (Anslået)

14. oktober 2027

Studieafslutning (Anslået)

20. juli 2028

Datoer for studieregistrering

Først indsendt

20. november 2024

Først indsendt, der opfyldte QC-kriterier

20. november 2024

Først opslået (Faktiske)

22. november 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • ITI-1284-302

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner